178 related articles for article (PubMed ID: 8070438)
1. Imipenem and meropenem induced resistance to beta-lactam antibiotics in Pseudomonas aeruginosa.
Giacometti A; Siquini FM; Cirioni O; Petroni S; Scalise G
Eur J Clin Microbiol Infect Dis; 1994 Apr; 13(4):315-8. PubMed ID: 8070438
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
Chen HY; Livermore DM
J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068
[TBL] [Abstract][Full Text] [Related]
3. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
Livermore DM; Yang YJ
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657
[TBL] [Abstract][Full Text] [Related]
4. Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa.
Zhou XY; Kitzis MD; Gutmann L
Antimicrob Agents Chemother; 1993 Jun; 37(6):1387-9. PubMed ID: 8328794
[TBL] [Abstract][Full Text] [Related]
5. Decreases of the susceptibility to low molecular weight beta-lactam antibiotics in imipenem-resistant Pseudomonas aeruginosa mutants: role of outer membrane protein D2 in their diffusion.
Gotoh N; Nishino T
J Antimicrob Chemother; 1990 Feb; 25(2):191-8. PubMed ID: 2109748
[TBL] [Abstract][Full Text] [Related]
6. Preferential selection of IMP and VIM metallo-beta-lactamases by imipenem in Pseudomonas aeruginosa.
Walsh F; Bracher S; Turner P; Amyes S
Chemotherapy; 2007; 53(6):407-9. PubMed ID: 17934261
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
[TBL] [Abstract][Full Text] [Related]
8. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544
[TBL] [Abstract][Full Text] [Related]
9. Imipenem-induced resistance to antipseudomonal beta-lactams in Pseudomonas aeruginosa.
Tausk F; Evans ME; Patterson LS; Federspiel CF; Stratton CW
Antimicrob Agents Chemother; 1985 Jul; 28(1):41-5. PubMed ID: 3929679
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
Livermore DM; Chen HY
J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
[TBL] [Abstract][Full Text] [Related]
11. In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia.
García-Rodríguez JA; García Sánchez JE; Muñoz Bellido JL; García Sánchez E; García García MI
J Chemother; 1991 Jun; 3(3):143-6. PubMed ID: 1919651
[TBL] [Abstract][Full Text] [Related]
12. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
Turner PJ
Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
[TBL] [Abstract][Full Text] [Related]
13. Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems.
Pournaras S; Ikonomidis A; Markogiannakis A; Spanakis N; Maniatis AN; Tsakris A
J Med Microbiol; 2007 Jan; 56(Pt 1):66-70. PubMed ID: 17172519
[TBL] [Abstract][Full Text] [Related]
14. [Participation of metallo-beta-lactamases in resistance to imipenem and meropenem in clinical strains of Pseudomonas aeruginosa and Acinetobacter spp].
Sacha P; Wieczorek P; Jakoniuk P; Zórawski M
Wiad Lek; 2008; 61(1-3):30-6. PubMed ID: 18717040
[TBL] [Abstract][Full Text] [Related]
15. Role of OmpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa.
Satake S; Yoneyama H; Nakae T
J Antimicrob Chemother; 1991 Aug; 28(2):199-207. PubMed ID: 1778851
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of disk diffusion test for carbapenem sensitivity in Acinetobacter baumannii and Pseudomonas aeruginosa strains].
Akan OA; Uysal S
Mikrobiyol Bul; 2005 Jul; 39(3):273-9. PubMed ID: 16358486
[TBL] [Abstract][Full Text] [Related]
17. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu YF; Liu CP; Wang NY; Shih SC
BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
[TBL] [Abstract][Full Text] [Related]
18. Molecular Characterization of Imipenem-Resistant, Meropenem-Susceptible Pseudomonas aeruginosa with blaVIM₋₂ Phenotype: Potential for Dissemination.
Pragasam AK; Raghanivedha M; Anandan S; Veeraraghavan B
Jpn J Infect Dis; 2016; 69(2):159-60. PubMed ID: 26567829
[No Abstract] [Full Text] [Related]
19. [in vitro activity of carbapenems against Enterobacteriaceae and Pseudomonas aeruginosa hyperproducers of group 1 chromosomal beta-lactamases].
Martínez-Beltrán J; Calderón C; Sierra MP; Alvarez M; Cantón R
Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():20-6. PubMed ID: 9410065
[TBL] [Abstract][Full Text] [Related]
20. Resistance emergence among P. aenrginosa in a rat thigh-abscess model. Comparison of imipenem and meropenem treatment.
Karadenizli A; Kolayli F; Okay E; Ergen K; Oz S; Savli H; Leblebicioglu H; Vahaboglu H
New Microbiol; 2003 Jul; 26(3):275-80. PubMed ID: 12901424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
